Paxlovid Is Now Less Effective Against Covid, Study Shows

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Canada Headlines News

Canada Latest News,Canada Headlines

In a real-world study of people with Covid-19, Pfizer Inc.’s antiviral Paxlovid was less effective at preventing the infection’s most serious cases than it was in initial trials.

The pill was just 37% effective at preventing hospitalization or death in high-risk patients when compared to no Covid treatment at all, according to an observational study published Thursday in JAMA Network Open. In earlier studies, it cut the risk of hospitalization or death by as much as 89%.

The study published Thursday measures how the drug is performing in the real world, rather than carefully designed and monitored clinical trials. Both the earlier trial and the newer study measured people at high risk of developing Covid complications. Despite the lower efficacy against hospitalization and death in the new study, the antiviral is still “definitely recommended for high-risk patients,” says Danyu Lin, a biostatistics professor at the University of North Carolina at Chapel Hill and lead author of the study.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in CA

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.